Renal updates by clinical finding

Dose or interval change

Levetiracetam (Roweepra), oral tablet

Renal measure

CrCl normalized to 1.73 m2, mL/min/1.73 m2

Renal action or finding

Use body-surface-area-adjusted CrCl to select the adult oral levetiracetam dose. Hemodialysis requires a supplemental dose after the session.

Limits and monitoring

Use the renal table for the exact oral product. Confirm the tablet strength and dosing interval.

Review 2 product or source cautions

Apply only to the stated formulation, indication and renal population.

DailyMed SPL version 5, posted May 26, 2025 | Selected sections checked 2026-11-07. Independent clinical review pending.

Dose or interval change

Levetiracetam (Spritam), oral tablet for suspension

Renal measure

CrCl normalized to 1.73 m2, mL/min/1.73 m2

Renal action or finding

Use body-surface-area-adjusted CrCl to select the adult oral levetiracetam dose. Hemodialysis requires a supplemental dose after the session.

Limits and monitoring

Use the renal table for the exact oral product. Confirm the tablet strength and dosing interval.

Review 1 product or source caution

Apply only to the stated formulation, indication and renal population.

DailyMed SPL version 29, posted Nov 17, 2025 | Selected sections checked 2026-11-07. Independent clinical review pending.

No adjustment within stated limits

Linagliptin (Tradjenta), oral tablet

Renal measure

Renal impairment categories as defined by the cited product label

Renal action or finding

Renal impairment does not require a change to the linagliptin dose.

Limits and monitoring

Apply this finding to the single-ingredient product. Fixed combinations can have different renal restrictions.

Review 1 product or source caution

Apply only to the stated formulation, indication and renal population.

DailyMed SPL version 12, posted Sep 08, 2025 | Selected sections checked 2026-11-07. Independent clinical review pending.

Insufficient evidence

Liraglutide (Saxenda), subcutaneous weight-management product

Renal measure

Renal impairment categories as defined by the cited product label

Renal action or finding

Clinical experience with weight-management liraglutide is limited across renal severity groups, including ESRD.

Limits and monitoring

Monitor for volume depletion, particularly during gastrointestinal adverse effects.

Review 1 product or source caution

Apply only to the stated formulation, indication and renal population.

DailyMed SPL version 22, posted Jun 15, 2026 | Selected sections checked 2026-11-07. Independent clinical review pending.

No adjustment within stated limits

Liraglutide (Victoza), subcutaneous injection

Renal measure

Renal impairment categories as defined by the cited product label

Renal action or finding

Liraglutide for diabetes does not require a renal dose reduction.

Limits and monitoring

Experience in end-stage renal disease is limited. Assess renal function with significant gastrointestinal fluid losses.

Review 1 product or source caution

Apply only to the stated formulation, indication and renal population.

DailyMed SPL version 31, posted Nov 17, 2025 | Selected sections checked 2026-11-07. Independent clinical review pending.

Insufficient evidence

Loncastuximab tesirine (Zynlonta), IV injection

Renal measure

Creatinine clearance (CrCl), mL/min

Renal action or finding

The effect of severe renal impairment or ESRD on the product's pharmacokinetics is unknown.

Limits and monitoring

A dialysis dose cannot be derived from the cited data.

Review 1 product or source caution

Apply only to the stated formulation, indication and renal population.

DailyMed SPL version 15, posted Jun 17, 2026 | Selected sections checked 2026-11-07. Independent clinical review pending.

Restriction or avoidance

Maraviroc (Selzentry), oral tablet

Renal measure

Creatinine clearance (CrCl), mL/min

Renal action or finding

At CrCl below 30 mL/min or in ESRD, potent CYP3A inhibitors or inducers contraindicate maraviroc. In adults without such interacting drugs, postural hypotension on 300 mg twice daily warrants reduction to 150 mg twice daily.

Limits and monitoring

Consider use in this renal population only if alternatives are unavailable. Check concomitant drugs, age and orthostatic symptoms.

Review 1 product or source caution

Apply only to the stated formulation, indication and renal population.

DailyMed SPL version 26, posted Jun 24, 2026 | Selected sections checked 2026-11-07. Independent clinical review pending.

Pharmacokinetics only

Mepolizumab (Nucala), subcutaneous injection

Renal measure

Creatinine clearance (CrCl), mL/min

Renal action or finding

Mepolizumab clearance at CrCl 50-80 mL/min resembled clearance in patients with normal kidney function.

Limits and monitoring

The population analysis provides limited information below the studied range.

Review 1 product or source caution

Apply only to the stated formulation, indication and renal population.

DailyMed SPL version 25, posted Oct 23, 2026 | Selected sections checked 2026-11-07. Independent clinical review pending.

Monitoring or toxicity

Mesalamine (Apriso), oral extended-release capsule

Renal measure

Renal impairment categories as defined by the cited product label

Renal action or finding

Mesalamine products have been associated with interstitial nephritis and renal failure. Assess renal function before treatment and periodically thereafter.

Limits and monitoring

Reassess treatment if renal function worsens. Verify the exact oral or rectal delivery system.

Review 1 product or source caution

Apply only to the stated formulation, indication and renal population.

DailyMed SPL version 36, posted Oct 22, 2026 | Selected sections checked 2026-11-07. Independent clinical review pending.

Monitoring or toxicity

Mesalamine (Canasa), rectal suppository

Renal measure

Renal impairment categories as defined by the cited product label

Renal action or finding

Mesalamine products have been associated with interstitial nephritis and renal failure. Assess renal function before treatment and periodically thereafter.

Limits and monitoring

Reassess treatment if renal function worsens. Verify the exact oral or rectal delivery system.

Review 1 product or source caution

Apply only to the stated formulation, indication and renal population.

DailyMed SPL version 32, posted Oct 26, 2026 | Selected sections checked 2026-11-07. Independent clinical review pending.

Monitoring or toxicity

Mesalamine (Delzicol), oral delayed-release capsule

This summary uses the identified dated label. Verify the current label for this presentation before applying the regimen.

Renal measure

Renal impairment categories as defined by the cited product label

Renal action or finding

Mesalamine products have been associated with interstitial nephritis and renal failure. Assess renal function before treatment and periodically thereafter.

Limits and monitoring

Reassess treatment if renal function worsens. Verify the exact oral or rectal delivery system.

Review 1 product or source caution

Verify the current prescribing information for this presentation.

DailyMed SPL version 3, posted Aug 08, 2016 | Selected sections checked 2026-11-07. Independent clinical review pending.

Monitoring or toxicity

Mesalamine (Lialda), oral delayed-release tablet

Renal measure

Renal impairment categories as defined by the cited product label

Renal action or finding

Mesalamine products have been associated with interstitial nephritis and renal failure. Assess renal function before treatment and periodically thereafter.

Limits and monitoring

Reassess treatment if renal function worsens. Verify the exact oral or rectal delivery system.

Review 1 product or source caution

Apply only to the stated formulation, indication and renal population.

DailyMed SPL version 50, posted Oct 28, 2026 | Selected sections checked 2026-11-07. Independent clinical review pending.